Distinct predictive immunogenomic profiles of response to immune checkpoint inhibitors and il-2: a 1 real-world evidence study of patients with advanced renal cancer 2 3 joel r. eisner , kirk d. beebe , gregory m. mayhew , yoichiro shibata , yuelong guo , carol farhangfar , 4 farhang farhangfar , joshua m. uronis , jill mooney , michael v. milburn , david foureau , richard l. 5 white , asim amin , marcos e. milla 6 genecentric therapeutics, inc. 7 levine cancer institute, atrium health 8 synthorx, inc – a sanofi company

HIGHLIGHTS

• who: Joel R. Eisner and collaborators from the Levine Cancer Institute have published the research work: Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL-2: A 1 Real-world Evidence Study of Patients with Advanced Renal Cancer 2 3 Joel R. Eisner , Kirk D. Beebe , Gregory M. Mayhew , Yoichiro Shibata , Yuelong Guo , Carol Farhangfar , 4 Farhang Farhangfar , Joshua M. Uronis , Jill Mooney , Michael V. Milburn , David Foureau , Richard L. 5 White , Asim Amin , Marcos E. Milla 6 GeneCentric Therapeutics, Inc. 7 Levine Cancer Institute, Atrium Health 8 Synthorx, Inc - A Sanofi Company, in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.